SG/CALL/UCB/140/0.1/20.12.24 Stock

1F67S

DE000SW779P0

Real-time Euronext Paris 08:48:21 2024-07-17 am EDT
1.48 ^EUR	-2.63%

Current month	+22.58%
1 month	+16.92%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart UCB

Latest news about UCB

UCB : spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN)	Jun. 28	PU
UCB : Financial Reporting Document	Jun. 26	PU
UCB : Financial Reporting Document	Jun. 26	PU
UCB : epilepsy drug BRIVIACT(brivaracetam) approved in Japan for treatment of focal onset seizures	Jun. 26	PU

More news

Quotes 5-day view

Date	Price	Change
24-07-17	1.48	-2.63%
24-07-16	1.52	-4.40%
24-07-15	1.59	0.00%
24-07-12	1.59	-2.15%
24-07-11	1.625	-1.22%

Real-time Euronext Paris

Last update July 17, 2024 at 08:48 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	UCB
Issuer	Société Générale
	1F67S
ISIN	DE000SW779P0
Date issued	2024-03-26
Strike	140 €
Maturity	2024-12-20 (156 Days)
Parity	10 : 1
Emission price	0.57 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.76 €
Lowest since issue	0.475 €
Spread	0.02 €
Spread %	1.33%

Company Profile

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sector

More about the company

Ratings for UCB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: UCB

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

142.6 EUR

Average target price

140.5 EUR

Spread / Average Target

-1.47%

Consensus